210 related articles for article (PubMed ID: 34500779)
1. Anticancer Activities of Hesperidin via Suppression of Up-Regulated Programmed Death-Ligand 1 Expression in Oral Cancer Cells.
Wudtiwai B; Makeudom A; Krisanaprakornkit S; Pothacharoen P; Kongtawelert P
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500779
[TBL] [Abstract][Full Text] [Related]
2. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients.
Kuo CS; Yang CY; Lin CK; Lin GJ; Sytwu HK; Chen YW
Biomed Pharmacother; 2021 Jan; 133():111057. PubMed ID: 33378962
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory Effect of Hesperidin on the Expression of Programmed Death Ligand (PD-L1) in Breast Cancer.
Kongtawelert P; Wudtiwai B; Shwe TH; Pothacharoen P; Phitak T
Molecules; 2020 Jan; 25(2):. PubMed ID: 31936263
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold.
Chen H; Wang K; Yang Y; Huang X; Dai X; Feng Z
Eur J Med Chem; 2021 May; 217():113377. PubMed ID: 33770574
[TBL] [Abstract][Full Text] [Related]
5. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
[TBL] [Abstract][Full Text] [Related]
6. Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy.
Xiong W; Qi L; Jiang N; Zhao Q; Chen L; Jiang X; Li Y; Zhou Z; Shen J
ACS Appl Mater Interfaces; 2021 Feb; 13(7):8026-8041. PubMed ID: 33577301
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationship and biological evaluation of 12 N-substituted aloperine derivatives as PD-L1 down-regulatory agents through proteasome pathway.
Zeng QX; Wang K; Zhang X; Shi YL; Dou YY; Guo ZH; Zhang XT; Zhang N; Deng HB; Li YH; Song DQ
Bioorg Chem; 2021 Dec; 117():105432. PubMed ID: 34678602
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
Gao T; Mao Z; Li W; Pei R
J Mater Chem B; 2021 Jan; 9(3):746-756. PubMed ID: 33319876
[TBL] [Abstract][Full Text] [Related]
10. Nano-diamino-tetrac (NDAT) inhibits PD-L1 expression which is essential for proliferation in oral cancer cells.
Lin SJ; Chin YT; Ho Y; Chou SY; Sh Yang YC; Nana AW; Su KW; Lim YT; Wang K; Lee SY; Shih YJ; Chen YR; Whang-Peng J; Davis PJ; Lin HY; Fu E
Food Chem Toxicol; 2018 Oct; 120():1-11. PubMed ID: 29960019
[TBL] [Abstract][Full Text] [Related]
11. Molecular hybridization used to design and synthesize neo-tanshinlactone derivatives as PD-1/PD-L1 inhibitors.
Zhang M; Liu J; Wang Y; Wang P; Morris-Natschke S; Lee KH
Bioorg Med Chem; 2022 Jan; 54():116579. PubMed ID: 34954618
[TBL] [Abstract][Full Text] [Related]
12. Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody.
He J; Zhang W; Di T; Meng J; Qi Y; Li G; Zhang Y; Su H; Yan W
Biomed Pharmacother; 2020 Nov; 131():110541. PubMed ID: 33152901
[TBL] [Abstract][Full Text] [Related]
13. Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer.
Hu W; Ma Y; Zhao C; Yin S; Hu H
Mol Carcinog; 2021 Nov; 60(11):746-757. PubMed ID: 34411338
[TBL] [Abstract][Full Text] [Related]
14. Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1α and STAT3.
Xing Y; Mi C; Wang Z; Zhang ZH; Li MY; Zuo HX; Wang JY; Jin X; Ma J
Pharmacol Res; 2018 Sep; 135():166-180. PubMed ID: 30103001
[TBL] [Abstract][Full Text] [Related]
15. In Situ PD-L1 Expression in Oral Squamous Cell Carcinoma Is Induced by Heterogeneous Mechanisms among Patients.
Kondo Y; Suzuki S; Ono S; Goto M; Miyabe S; Ogawa T; Tsuchida H; Ito H; Takahara T; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456895
[TBL] [Abstract][Full Text] [Related]
16. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
[No Abstract] [Full Text] [Related]
17. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.
Yuan LW; Jiang XM; Xu YL; Huang MY; Chen YC; Yu WB; Su MX; Ye ZH; Chen X; Wang Y; Lu JJ
Phytomedicine; 2021 Jan; 80():153394. PubMed ID: 33130472
[TBL] [Abstract][Full Text] [Related]
18. Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors.
Knopf P; Stowbur D; Hoffmann SHL; Hermann N; Maurer A; Bucher V; Poxleitner M; Tako B; Sonanini D; Krishnamachary B; Sinharay S; Fehrenbacher B; Gonzalez-Menendez I; Reckmann F; Bomze D; Flatz L; Kramer D; Schaller M; Forchhammer S; Bhujwalla ZM; Quintanilla-Martinez L; Schulze-Osthoff K; Pagel MD; Fransen MF; Röcken M; Martins AF; Pichler BJ; Ghoreschi K; Kneilling M
Mol Cancer; 2023 Dec; 22(1):207. PubMed ID: 38102680
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
20. Chitosan oligosaccharide regulates AMPK and STAT1 pathways synergistically to mediate PD-L1 expression for cancer chemoimmunotherapy.
Chen J; Zhou Z; Zheng C; Liu Y; Hao R; Ji X; Xi Q; Shen J; Li Z
Carbohydr Polym; 2022 Feb; 277():118869. PubMed ID: 34893274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
